Last reviewed · How we verify
NCT02026505
Evaluation of Cardiotoxic Effects of Bortezomib
trial testing Bortezomib in Multiple Myeloma in 11 participants. Completed in 1 March 2019.
31 December 2016
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 1 March 2014 |
| Primary completion | 31 December 2016 |
| Estimated completion | 1 March 2019 |
Drugs / interventions tested
- Bortezomib (bortezomib) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Heart Failure, Systolic — all drugs for Heart Failure, Systolic →
- Cardiotoxins — all drugs for Cardiotoxins →
Sponsor
Oregon Health and Science University
Who can join
Adults 18 to 70, any sex, with Multiple Myeloma or Heart Failure, Systolic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple myeloma is not being studied here. The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02026505
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bortezomib
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02026505 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 13 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02026505.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing